PharmaGap Announces Option Grants to Officers and Directors



    OTTAWA, Feb. 19 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap"
or "the Company") today announced the grant of options to purchase common
shares to a number of its directors and officers as follows:

    
    Dr. Jenny Phipps,        Chief Scientific Officer and Director   350,000
    Dr. Michel Phipps,       Director                                170,000
    Mr. Dan Larkin,          Director                                100,000
    Mr. Robert Letellier,    Director                                170,000
    Mr. Simon Goulet         Chief Operating Officer                 250,000
    Mr. Gerald Leahy         Chief Financial Officer                 150,000
    

    The Options granted have an exercise price of $0.15 per common share,
expire on February 18, 2014, and vest immediately.
    In addition to granting the shares set out above, the Company also
granted options to other employees and consultants.

    About PharmaGap Inc.

    PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology
company with a core focus on developing novel therapeutic compounds for the
treatment of cancer. PharmaGap's research platform targets cellular signalling
pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug
compound, PhG-alpha-1, is in preclinical development and targets PKC alpha.
The Company's strategy is to out-license drug compounds to larger life
sciences companies at the preclinical stage. For more information on PharmaGap
please visit the Company's website at www.pharmagap.com.

    
    Note: The TSX-Venture Exchange does not accept responsibility for the
    adequacy or accuracy of this release. No Securities Commission or other
    regulatory authority having jurisdiction over PharmaGap has approved or
    disapproved of the information contained herein. This release contains
    forward looking statements that may not occur or may change materially.
    




For further information:

For further information: Robert McInnis, President & CEO, (613)
990-9551, bmcinnis@pharmagap.com

Organization Profile

PharmaGap Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890